AstraZeneca plc  

(Public, LON:AZN)   Watch this stock  
Find more results for AZN
4,009.50
+50.00 (1.26%)
Apr 29 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 3,926.82 - 4,107.45
52 week 3,746.00 - 4,678.34
Open 3,962.50
Vol / Avg. 0.00/2.39M
Mkt cap 50.46B*
P/E 26.23
Div/yield 131.00/4.70*
EPS 1.53*
Shares 1.26B
Beta     -
Inst. own     -
*GBP
Jul 28, 2016
Q2 2016 AstraZeneca PLC Earnings Release Add to calendar
Jun 7, 2016
AstraZeneca PLC Analysts and Investors Briefing during the American Society of Clinical Oncology (ASCO) Annual Meeting - 12:30AM GMT+1 - Add to calendar
Apr 29, 2016
AstraZeneca PLC Annual Shareholders Meeting
Apr 29, 2016
Q1 2016 AstraZeneca PLC Earnings Call
Apr 29, 2016
Q1 2016 AstraZeneca PLC Earnings Release
Mar 31, 2016
AstraZeneca PLC at Bank of America Merrill Lynch Investor Relations Insights Conference
Mar 18, 2016
AstraZeneca PLC at Carnegie Healthcare Seminar
Mar 15, 2016
AstraZeneca PLC at Barclays Global Healthcare Conference
Mar 15, 2016
AstraZeneca PLC at Exane Bnp Healthcare Conference
Mar 7, 2016
AstraZeneca PLC at Cowen Health Care Conference
  

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 12.63% 11.44%
Operating margin 17.00% 16.65%
EBITD margin - 28.89%
Return on average assets 5.67% 4.76%
Return on average equity 18.09% 14.82%
Employees 61,500 -
CDP Score - 97 B

Address

- Legal Department, 2 Kingdom Street
LONDON, W2 6BD
United Kingdom - Map
+44-20-73045000 (Phone)
+44-20-76048151 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9), a treatment for hyperkalaemia, a condition associated with increased mortality in patients with chronic kidney disease (CKD), diabetes mellitus (DM) and chronic heart failure (CHF).

Officers and directors

Pascal Soriot Chief Executive Officer, Executive Director
Age: 56
Marc Dunoyer Chief Financial Officer, Executive Director
Age: 62
Fiona Cicconi Executive Vice-President, Human Resources
Sean Bohen M.D. Ph.D. Chief Medical Officer, Executive Vice President - Global Medicines Development
Ruud Dobber Executive Vice President, Europe
Paul Hudson President, AstraZeneca, US and Executive Vice-President, North America
Bahija Jallal Ph.D. Executive Vice President, MedImmune
Mark Mallon Executive Vice President, International
Luke Miels Executive Vice-President, GPPS
Menelas Pangalos Executive Vice President - Innovative Medicines